As of early 2025, tuberculosis cases are increasing in the U.S. This disease, often shortened to TB, causes significant lung damage and, if not treated, is almost always lethal.

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target dropped by HC Wainwright from $22.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage ...